Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1

Conditions

Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Carcinoma 1

Interventions

Cisplatin 314Radiotherapy 139Cetuximab 132pembrolizumab 131Docetaxel 121Carboplatin 119Radiotherapy, Intensity-Modulated 97Fluorouracil 94Paclitaxel 92Nivolumab 64Gemcitabine 50toripalimab 46Radiation 44Drug Therapy 39Capecitabine 39Magnetic Resonance Spectroscopy 38Surgical Procedures, Operative 33camrelizumab 31130-nm albumin-bound paclitaxel 28apatinib 27tislelizumab 26Chemoradiotherapy 26Specimen Handling 25Bevacizumab 24durvalumab 23Albumin-Bound Paclitaxel 23nimotuzumab 22lenvatinib 21Sorafenib 21Platinum 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Interviews as Topic × Head & Neck × Clear all
NCT06997068 2026-05-11

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population

Mayo Clinic

Phase 2 Recruiting
25 enrolled
Head & Neck

Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡